ライフサイエンスコーパス: prostatic acid phosphatase

1 f-assembling peptide fragment of the protein prostatic acid phosphatase.

2 esigned to stimulate T-cell immunity against prostatic acid phosphatase.

3 cell products, such as androgen receptor and prostatic acid phosphatase.

4 to that observed in the structural homologue prostatic acid phosphatase.

5 he yeast phosphoglycerate mutase and the rat prostatic acid phosphatase.

6 -nucleotidase, NT5E, and to a lesser extent, prostatic acid phosphatase.

7 (DIA-MS) were quantitatively analyzed, where prostatic acid phosphatase (ACPP), clusterin (CLU), alph

8 They express prostatic acid phosphatase and androgen receptors and re

9 mation seen in the distantly related enzymes prostatic acid phosphatase and fructose-2,6-bisphosphata

10 PAP(248-286) is a peptide fragment of prostatic acid phosphatase and has been reported to form

11 y increased expression of tartrate-sensitive prostatic acid phosphatase as a broadly acting ectonucle

12 re cocultured ex vivo with recombinant mouse prostatic acid phosphatase as the target neoantigen.

13 argets such as prostate-specific antigen and prostatic acid phosphatase as well as, more recently, an

14 graphic studies compiled on the tartrate-rat prostatic acid phosphatase binary complex erroneously po

15 rhK4 also completely degraded prostatic acid phosphatase but failed to cleave serum al

16 In semen, proteolytic peptide fragments from prostatic acid phosphatase can form amyloid fibrils term

17 52(Shc) tyrophosphorylation was decreased in prostatic acid phosphatase cDNA-transfected stable subcl

18 s a two-domain fold similar to that of human prostatic acid phosphatase, consisting of an alpha/beta

19 on of fast-growing cells by cellular form of prostatic acid phosphatase (cPAcP) expression, a negativ

20 Cellular prostatic acid phosphatase (cPAcP), an authentic tyrosin

21 Human prostatic acid phosphatase crystals soaked in N-propyl-L

22 ty of protein tyrosine phosphatase, cellular prostatic acid phosphatase, decreased correspondingly in

23 FtHAP and human prostatic acid phosphatase differ in the orientation of

24 rtrate, which does not significantly inhibit prostatic acid phosphatase, does not form strong hydroge

25 ining the cloned TCR sequences reactive with prostatic acid phosphatase epitopes.

26 t with autologous dendritic cells expressing prostatic acid phosphatase (for prostate cancer) or with

27 r of virus infection (SEVI) originating from prostatic acid phosphatase greatly increase XMRV infecti

28 artrate-refractory, which is reported as the prostatic acid phosphatase level.

29 The structure of human prostatic acid phosphatase, noncovalently bound in N-pro

30 state-specific androgen-responsive antigens, prostatic acid phosphatase (PAcP) and prostate-specific

31 The cellular form of human prostatic acid phosphatase (PAcP) is a neutral protein-t

32 Human prostatic acid phosphatase (PAcP) is a prostate epitheli

33 ast partly regulated by the cellular form of prostatic acid phosphatase (PAcP), a prostate-unique pro

34 el of ErbB-2, which is regulated by cellular prostatic acid phosphatase (PAcP), a protein tyrosine ph

35 tients immunized with a DNA vaccine encoding prostatic acid phosphatase (PAP) and a trans-vivo delaye

36 Prostatic acid phosphatase (PAP) and ecto-5'-nucleotidas

37 ing fragments of the abundant semen proteins prostatic acid phosphatase (PAP) and semenogelins form a

38 cs LSGraph and Ingenuity Systems) identified prostatic acid phosphatase (PAP) as an enzyme overexpres

39 The X-ray crystal structure of human prostatic acid phosphatase (PAP) in complex with a phosp

40 f a DNA vaccine (pTVG-HP [MVI-816]) encoding prostatic acid phosphatase (PAP) in patients with recurr

41 Prostatic acid phosphatase (PAP) is a prostate cancer-as

42 Prostatic acid phosphatase (PAP) is a prostate tumor ant

43 Prostatic acid phosphatase (PAP) is expressed in nocicep

44 Prostatic acid phosphatase (PAP) is just such an Ag that

45 Prostatic acid phosphatase (PAP) is uniquely expressed i

46 h a recombinant fusion protein consisting of prostatic acid phosphatase (PAP) linked to granulocyte-m

47 -free methodology is able to report on human prostatic acid phosphatase (PAP), a tumor marker, with a

48 ltimodal immunopeptidomic analyses for human prostatic acid phosphatase (PAP), a well-recognized tiss

49 is identical to the transmembrane isoform of prostatic acid phosphatase (PAP), an enzyme with unknown

50 tigens, prostate-specific antigen (PSA), and prostatic acid phosphatase (PAP), and is derived from th

51 on-induced pain may be mediated by decreased prostatic acid phosphatase (PAP), as PAP levels are mark

52 III study using Sipuleucel-T, an autologous prostatic acid phosphatase (PAP)-loaded dendritic cell i

53 sine by ecto-5'-nucleotidase (NT5E, CD73) or prostatic acid phosphatase (PAP, ACPP).

54 ted with KHT-1, while its mammalian homolog, prostatic acid phosphatase (PAP; also known as ACPP-201)

55 r peptide (a proteolytic cleavage product of prostatic acid phosphatase, PAP(248-286)).

56 ntigen, and vaccines such as those targeting prostatic acid phosphatase, prostate-specific antigen, a

57 ess a potent ectonucleotidase, transmembrane prostatic acid phosphatase (TMPAP), in the SSFP region.